To further validate the novel PABL-based ELISA assay, lysates of primary leukemic cells derived from two patients, one affected by chronic myeloid leukaemia (p210 BCR-ABL1 positive, Pt#1) and another by ALL (BCR-ABL1 negative, Pt#2), were also used. The gene discussed is EVPL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.